IFNA2 and breast carcinoma: Consistently, it was observed that IFNα2b treatment desensitized MCF7 cells to palbociclib with higher IC50 values, especially in the high dose group (Fig. S3H), suggesting activation of the IFN signaling confers CDK4/6i resistance in breast cancer cells.